Sana Biotechnology (SANA) Competitors

Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.

Does the MarketBeat Community favor KNSA or SANA?

Kiniksa Pharmaceuticals received 151 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 65.54% of users gave Kiniksa Pharmaceuticals an outperform vote while only 64.86% of users gave Sana Biotechnology an outperform vote.

Company	Underperform	Outperform
Kiniksa Pharmaceuticals	Outperform Votes 175 65.54%	Underperform Votes 92 34.46%
Sana Biotechnology	Outperform Votes 24 64.86%	Underperform Votes 13 35.14%

Does the media refer more to KNSA or SANA?

In the previous week, Sana Biotechnology had 4 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 22 mentions for Sana Biotechnology and 18 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 0.80 beat Sana Biotechnology's score of 0.07 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals believe in KNSA or SANA?

54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are owned by insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has preferable valuation and earnings, KNSA or SANA?

Kiniksa Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals	$423.24M	4.63	$14.08M	-$0.61	-44.21
Sana Biotechnology	N/A	N/A	-$283.26M	-$1.16	-1.64

Which has more volatility and risk, KNSA or SANA?

Kiniksa Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Do analysts rate KNSA or SANA?

Kiniksa Pharmaceuticals currently has a consensus price target of $38.00, suggesting a potential upside of 40.90%. Sana Biotechnology has a consensus price target of $10.80, suggesting a potential upside of 468.42%. Given Sana Biotechnology's higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Kiniksa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sana Biotechnology	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Is KNSA or SANA more profitable?

Sana Biotechnology has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals	-2.36%	-7.31%	-5.95%
Sana Biotechnology	N/A	-84.22%	-44.97%

Summary

Kiniksa Pharmaceuticals beats Sana Biotechnology on 10 of the 16 factors compared between the two stocks.